Dr. Juliane Bernholz has over 27 years of experience working in the pharmaceutical and biotech industry in a variety of senior R&D and business development roles. She joined AM-Pharma as Chief Operating Officer in October 2019.
Prior to joining AM-Pharma Juliane was a Compound Development Team Leader at Janssen R&D LLC in New Jersey, US where she was responsible for leading the development of a next generation anticoagulant and CRISPR-Cas3 enhanced bacteriophage therapy.
Before her time at Janssen, Dr. Bernholz held a number of international leadership roles in big Pharma and Biotech companies. These included Lead for International Partnering in the Diabetes Division at Sanofi-Aventis in Frankfurt, Germany where she successfully executed a cell therapy and drug discovery collaboration deal. She also served as Senior Global Program Head of the Critical Care Franchise at Novartis Pharma, where she led work on its cystic fibrosis projects. Her prior career included a variety of senior roles at Actelion, Novartis, Ciba and Sandoz .
Juliane holds a PhD in Cell biology from the Biozentrum of the University of Basel, Switzerland.